MetaCap

Bolt Biotherapeutics (BOLT) vs Seres Therapeutics (MCRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Bolt Biotherapeutics is the larger company by market cap ($12.8 million vs $12.6 million), about 1.0 times the size. Seres Therapeutics converts more of its revenue into profit, with a net margin of 721.9% versus -433.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLT+36.39%MCRB-54.41%
+90%+14%-61%
Oct 7, 20261 yearNov 20, 2026
BOLT+19.46%MCRB-54.24%
+66%+3%-60%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLT versus MCRB key metrics
MetricBOLTMCRB
Share price$4.91$1.24
Market cap$12.80M$12.64M
1-day change-2.96%-6.77%
EPS (TTM)$-14.00$-5.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.70M$789.00K
Revenue growth (YoY)+0.07%—
Net income (latest FY)$-33.38M$5.70M
Operating margin-469.30%-11910.14%
Net margin-433.74%721.93%
52-week high$7.78$18.86
52-week low$3.10$1.20
Distance from 52-week high-36.89%-93.43%
Analyst consensusnonenone
Avg. price target upside+490.63%+1270.97%
Average volume257.43K74.83K
Shares outstanding2.61M10.20M
Employees2366
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Seres Therapeutics is more profitable, keeping 721.9 cents of every revenue dollar as net income versus -433.7 cents for Bolt Biotherapeutics.

About Bolt Biotherapeutics

BOLT stock →

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.

Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees

About Seres Therapeutics

MCRB stock →

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation.

Health Care · Biotechnology: Pharmaceutical Preparations · 66 employees

BOLT vs MCRB FAQ

Which is bigger, Bolt Biotherapeutics or Seres Therapeutics?

Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $12.80M compared with $12.64M for Seres Therapeutics (MCRB).

Are Bolt Biotherapeutics and Seres Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons